Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid Tumors Rapid oral presentation title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. Observations in the abstract include: Presentation Details: Abstract #: 6014 Session Title: Head and Neck Cancer Session Date and Time: June 3, 2024, 8:00-9:30 a.m. CT As full presentations become available at the 2024 ASCO® Annual Meeting, they will cont ...